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Abstract
Background: Diabetes mellitus (DM) is a major health problem in the United Arab Emirates (UAE) and is well
recognized as a major and increasing burden to the country’s resources due to its severe, long term debilitating
effects on individuals, families and the society at large. The aim of the study was to estimate the direct annual
treatment costs of DM and its related complications among patients in Al-Ain city, UAE.
Methods: A sample of 150 DM patients were enrolled during 2004-2005, and their medical costs over the ensuing
12 months was measured, quantified, analyzed and extrapolated to the population in Al-Ain and UAE, using
conventional and inference statistics. The costs were converted from UAE Dirhams to US Dollar, using the official
conversion rate of US$ (1 USD = 3.68 AED).
Results: The total annual direct treatment costs of DM among patients without complications in Al Ain-UAE, was
US $1,605 (SD = 1,206) which is 3.2 times higher than the per capita expenditure for health care in the UAE (US$
497) during 2004 (WHO, 2004). However, this cost increased 2.2 times with the presence of DM related
complications for patients with microvascular complications, by 6.4 times for patients with macrovascular
complications and 9.4 times for patients with both micro and macrovascular complications. Likewise, the annual
direct hospitalization costs of DM patients increased by 3.7 times for patients with microvascular complications, by
6.6 times for patients with macrovascular complications and by 5 times for patients with both micro and
macrovascualr complications. Overall, costs increased with age, diabetes duration and were higher for patients
treated with insulin compared to those treated with oral hypoglycemic agents or with diet control only.
Conclusions: DM direct treatment costs increased with the presence and progression of chronic DM related
complications. Hospitalisation costs constituted a large proportion and were increasingly higher with the presence
and progression of DM related complications. To reduce the impact on healthcare resources, efforts should be
made to prevent progression to DM complications, by implementing guidelines for diabetes care, screening for
complications and better management.
Background
Diabetes Mellitus (DM) is a major cause of morbidity,
disability and mortality worldwide [1]. In addition, the
economic burden on patients and society in the form of
direct and indirect costs is enormous [1]. The IDF pro-
jections show that the health care expenditures on dia-
betes will account for 11.6% of the total healthcare
expenditure in the world in 2010 [1]. A recent study in
the U.S. estimated that annual costs in 2007 exceeded
US $174 billion [2]. A similar study in Italy showed that
the direct costs of healthcare in 2006 were €2,589 per
DM patient, compared to €1,682 for matched people
without diabetes [3]. In Europe, the CODE-2 study
showed that more than 10 million people with type 2
diabetes across eight European countries cost over EUR
29 billion in 1999 M [4].
The prevalence of diabetes in the United Arab Emi-
rates (UAE) is reportedly among the highest in the
world [1]. A population survey in Al Ain, UAE, in 2000
estimated the prevalence of DM at 25% among nationals
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GCC countries and expatriates) [5]. Another recent
study in the UAE showed that 19% of diabetic patients
suffered from DM retinopathy, 35% from DM neuropa-
thy, 12% from peripheral vascular disease, 14% from
coronary artery disease, 4% from cerebro-vascular dis-
ease, 35% from hypertension and 31% from dyslipidae-
mia [6,7]. The Ministry of Health in the UAE also
reported that DM constitutes the 6th leading cause of
death in the population [8].
Nevertheless, with only three studies from countries in
the region (Iran, Tunisia and Egypt) there is a dearth of
information on the economic impact of DM in the Mid-
dle East [9-12], especially the Arabian Peninsula, where
no specific studies were carried out. WHO estimates for
the per capita expenditure on health care in the region
amounted to US$ 497 for UAE during 2004 [13]. To fill
this gap we attempted to estimate the economic impact
of DM in Al-Ain district, UAE. Al Ain district is located
in the interior of Abu Dhabi Emirate and is the second
largest city after Abu-Dhabi with population of (approxi-
mately 500,000). This study aims to estimate the overall
patient treatment costs of DM in this part of the UAE;
including the direct management costs of the disease
a n di t sr e l a t e dc h r o n i cm a cro and micro-vascular
complications.
The earliest studies that attempted to measure the
economic impact of DM used the Cost of Illness (COI)
approach. This approach, originated by Mushkin [14],
Weisbrod [15], Rice [16], and others in the early 1960s,
estimates the direct economic burden of diseases, with
the single objective of priority setting in health care
planning. However, subsequent DM cost studies were
more complex [17] and considered costs due to co-mor-
bidity making use of either existing data, e.g. routine
data collected by the health care system and cost projec-
tions from previous studies [17], or collected new data,
e.g. using surveys of the DM population [18]. Most
recent DM cost studies are based on either national dia-
betic population surveys or on routinely collected data
that only attribute medical management costs to DM
when the disease is listed as the (primary) diagnosis for
a health care visit, disability or cause of death [18].
Thus, many of those studies tend to underestimate DM
costs as they ignore costs caused by other illnesses in
which DM is a contributory factor. The ideal approach
would be to assess all costs that would have been
averted ("avertable” costs) in the counterfactual situation
in which DM would have been eliminated [19]. How-
ever, this is methodologically complex, as such avertable
costs are not directly observable, and empirical studies
face major challenges such as confounding [15]. While
advanced statistical methods are often used to overcome
such problems it is not clear to what extent findings are
sensitive to the assumptions that enter into such calcu-
lations [16].
Methods
The view point of this study is that of the health care
system, i.e. it attempts to assess the direct treatment
costs imposed by DM and its related complications on
the health care sector of the country. Indirect costs such
as productivity losses resulting from lost work days,
which may be even larger than the direct medical costs,
were not considered. To estimate these costs per indivi-
dual patient (unit), we explored the treatment profiles of
a (cross-sectional) sample of DM patients over a one
year period. Clinical information about type of diabetes,
diabetes related complications and co-morbidity, severity
and treatment profile of patients were based on diagno-
sis and judgements by treating doctors.
1. Setting
The study was carried out at the two major hospitals,
Tawam and Al-Ain, serving 75% of patients in the East-
ern District of Abu Dhabi emirate (Al-Ain region). The
health care system in the region at the time was orga-
nised along the lines of the conventional health care sys-
tem, i.e. primary health care, through which 18 clinics
provide basic health care to DM patients, and secondary
and tertiary care to patients through the two referral
hospitals in the region: Tawam and Al-Ain. Provision of
health care at the time was administered through a
health insurance scheme for both nationals and non
nationals. Patients of all nationalities used to have equal
access to health care services with exception of non
health card holders. Patients with chronic complications
such as DM had equal right to access treatment at both
hospitals. At present, health care is free for local citizens
and effective from 2006, all non local residents of Abu
Dhabi are covered by a new obligatory comprehensive
health insurance scheme.
2. Study design and selection of participants
The study was part of a general cross-sectional survey of
DM patients carried out earlier to assess and establish
the prevalence of DM complications among diabetic
patients in Al-Ain District, UAE [6,7]. The sampling
frame of the study included all UAE and non-UAE dia-
betic patients of all ages and both genders, attending the
outpatient clinics of the two main referral hospitals (Al-
Ain and Tawam hospitals) for DM care. In the absence
of diabetes registries, patients were randomly selected
from the lists of clinic appointments. The study period
(for cost calculations) was the year preceding this index
visits. Sample sizes were based on the requirement that
prevalence estimates should have an (absolute) standard
error of no more than 0.02 (2%). Accordingly, a sample
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513 (82%) agreed to enrol, of whom 150 (29.3%) patients
were enrolled from the two diabetics clinics of the two
hospitals. The study was approved by the Ethics Com-
mittee of the Faculty of Medicine and Health Sciences
of the UAE University.
3. Data collection and definitions
Although a vast majority of DM patients receive regular
treatment at primary health care clinics in Al-Ain dis-
trict, the current system of primary medical care in Al-
Ain is not based on continuity of care and accountabil-
ity but rather on rapid access without appointment to
any physician available. Chronic disease clinics that have
been recently implemented in three primary centres
may have an impact on quality of care but due to logis-
tical reasons (data completeness and accessibility), only
patients attending outpatient clinics at Al- Ain and
Tawam hospitals were included in the study.
Consenting hospital patients were asked to complete
an interviewer administered questionnaire on frequency
of initial and follow up visits, hospital admissions and
all medical support causally related to DM management
during the past 12 months to validate hospital and clinic
data. Clinical data for patients were retrieved from their
medical records at the two hospitals.
It was not always possible to distinguish clearly
between types 1 and 2 diabetes from the medical
records alone and for that we opted to use the terms
“insulin treated diabetes”,a n d“non-insulin treated dia-
betes” to classify DM patients. The following sequelae of
chronic diabetic cardiovascular complications were con-
sidered for analysis: (1) Macro-vascular complications:
acute myocardial infarction, angina pectoris, stroke, and
non-traumatic amputation and foot ulcers; (2) Micro-
vascular complications: various levels of nephropathy (i.
e. microalbuminuria, clinical proteinuria and chronic
renal failure), retinopathy (i.e. background and prolifera-
tive retinopathy, macular edema, cataract and blindness)
and peripheral neuropathy. The diagnosis of various
chronic complications of DM was based on medical
records.
To assign costs to the care received by patients, the
study used the official list of charges/rates for patients
not covered by health insurance at the time (the official
rates for non health card holders). Those charges/prices
were allegedly based on approximate real costs; i.e. the
rates which, if charged to all individual patients, would
have covered the actual costs incurred to provide these
services without significant profits and/or subsidies. The
average unit costs per patient were estimated by using
expert opinion (consultants and doctors from participat-
ing hospitals) to distinguish and verify from the files of
individuals patients, health care consumption by
individual patients (including accommodation, pharma-
ceuticals, laboratory, nursing costs etc), likely received
for DM related conditions and that for other- unrelated-
reasons. Costs for DM related conditions were then
assigned by calculating the charges that non-card
holders would have paid for such health care services.
These unit costs were then extrapolated to all patients
whether he/she had actually paid for them or not (UAE
nationals are automatically insured against all medical
costs). To comprehend the combined cost impact of
DM complication on health care resources, the study
calculated and compared the treatment costs of DM
patients without complications to those of patients with
micorvascualr complications, those with macrovasualr
complications and those with both, macro and micro-
vascualr complications.
4. Statistical Analysis
Data entry and analysis was performed using the statisti-
cal software package (SPSS version 13). Cost estimates
are presented as point estimates with associated stan-
dard deviations. The study used conventional methods
of statistical inference and hypothesis testing. The Chi-
square test and the t-test were used, where appropriate,
to test for significance (p < 0.05 is considered statisti-
cally significant). Linear regression, with logarithmically
transformed costs as the dependent variable, was used
to estimate the simultaneous effect of various patient
characteristics on costs. A logarithmical transformation
was used, as patients characteristics were believed to act
multiplicatively on costs rather than additively. As ran-
dom selection of patients attending the clinic may lead
to size-biased sampling (those attending the clinic more
frequently are oversampled), the number of visits of a
patient to the clinic was treated as a “design” variable
and either used (inversely) as a weighting factor, or




A total of 150 DM patients were enrolled; 63% from
Tawam hospital and 37% from Al-Ain hospital. Of the
total sample 67% were males, 48% were UAE nationals,
7% were citizens from other Gulf (GCC) countries, 30%
were resident Arabs from other countries and 15% were
expatriate Asians living and working in the UAE. Thirty
three percent were above sixty years. The mean age was
55.6 years (SD: 13.3: range 14-85) and 46% were illiter-
ate (Table 1).
2. Clinical History of the Sample Population
Fifty-seven percent of the sample populations were ‘non
insulin treated’ DM patients. Forty- percent had the
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treated’ DM patients (Table 2).
3. Patients’ Treatment and Care Profile for DM and its
related complications
Patients’ attendance to the two clinics during the study
period varied largely: 26% of patients visited the clinic
7-8 times, 37% paid 3-6 visits, 17% paid 1-2 visits and
only 8% did not visit the clinics at all during the pre-
vious year. Fifty-one percent of the population had a
test for HbA1C in the previous year, 91% took a test for
fasting blood sugar, 69% for fasting lipid and 69% for
renal function, 63% had urinalysis, 38% were tested for
urine microscopy, 49% for microalbuminuria and 29%
had a 24-hour collection for proteins and creatinine
clearance during the past year (Table 3).
The analysis of the clinical treatment profile of DM
patients during the study period showed that 54% per-
cent had been admitted to hospital at least once for DM
related complications, 27% were admitted twice, 9%
were admitted three times or more and only 10% had
not required any hospital admission. During the study
period, 19% of the sample patients were admitted at
least once to the emergency room (ER) due to DM
complication, while 20% were taken to the ER for about
2-5 times (Table 3).
Concomitant risk factors, among patients with DM
related complications, were very common: 53% had high
cholesterol levels, out of which 44% were on lipid lower-
ing agents. Fifty-eight percent (95% CI: 50.1-65.9%) had
hypertension, out of whom 54% were on antihyperten-
sive treatment. Eighty-one percent (95% CI: 75.1-87.5%)
had symptomatic peripheral neuropathy, 35% had a his-
tory of foot or leg ulcers, and 11% had a history of
amputation due to diabetes.
The analysis of the clinical history of the sample
population showed that 69% underwent an ECG exami-
nation during the study year. Sixty percent reported a
history of heart disease, 28% reported a history of heart
attack and 15% had a history of heart operation(s).
Twenty percent had a history of stroke of whom, 90%
received treatment in the hospital ward and only 9%
had physiotherapy. Thirty-three percent of stroke
patients had spent at least one week in the hospital fol-
lowing stroke attack and 66% spent more than a week
(Table 4). Fifty-eight percent (95% CI: 50.2-66%) had
diabetic retinopathy; out of whom 42% were tested for
visual acuity, while 46% had eye pressure measurement
Table 1 Average Annual Treatment Costs in US $ by Patient Demographic Characteristics and Health Care Centre in
the UAE, during 2004 (N = 150)
Patient Socio Demographic Characteristics N %(95% C.I) Mean $ Annual Cost Std Deviation
Participant Health Care Centre Tawam hospital 95 63.3 (55.6-71.0) 5,262 5,980
Al-Ain Hospital 55 36.7 (29.0-44.4) 5,096 5,779
Sex Male 101 33% (25.5-40.5) 5,470 6,028
Female 48 67% (59.5-74.5) 4,646 5,609
Education level Illiterate 55 46% (38.0-54.0) 5,602 5,747
Primary school 48 27% (20.2-34.4) 4,473 6,388
Secondary school 20 19% (9.0-20.4) 4,583 4,880
Completed University 26 6% (6.8-17.2) 6,078 6,567
Nationality UAE 50 48% (40.4-56.0) 5,645 5,966
GCC 4 7% (2.9-11.1) 7,025 5,532
Other Arabs 59 30% (22.7-37.3) 4,417 6,016
Asians 35 15% (9.3-20.7) 4,304 5,405
Occupation Housewife or Retired 70 57.0% (49.1-64.9) 5,493 5,876
Employee 42 22.8% (16.1-29.6) 5,650 6,759
Labourer 33 16.8% (10.8-22.8) 4,334 5,260
Student 3 3.4% (0.5-6.3) 2,350 976
Age Group <20 yr 1 0.4% 2,610 1,492
20 - 39 yr 10 7% (3.7-12.3) 1,328 1,331
40 - 60 yr 99 59% (51.1-66.9) 4,759 5,939
>=61 yr 38 33% (25.5-40.5) 6,175 6,647
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Of the total sample 17% had a history of laser treatment
for retinopathy and 21% had (ever) undergone cataract
extraction. Thirty-four percent had diabetic nephropa-
thy, out of which 14% experienced chronic renal failure.
Of those who had renal failure, 71% were on haemodia-
lysis and 29% had undergone kidney transplantation
(Table 4).
The assessment of the overall health status showed
that 61% reported to have suffered poor health during
the past month (before the survey) while 39% reported
to have good health status (Table 4).
4. Direct Treatment Costs of Diabetes Mellitus
Table (1) shows the unit management costs of diabetes
by various patient characteristics; male treatment costs
were higher, compared to females (mean $5,470 vs.
$4,646) and treatment costs were also higher among
patients from neighbouring Gulf Council countries
(GCC) (Table 1). The annual mean treatment cost of a
GCC patient amounted to $7,025 compared to $5,645
per UAE patient or $4,304 per Asian patient. DM treat-
ment costs among patients also increased with increas-
ing age (Table 1). Young patients, aged 20-39 years, had
the lowest annual mean treatment cost viz. $2,610 com-
pared to $6,175 for those aged 61 years and above
(Table 1). Likewise, DM management costs increased
with duration of disease. Those who had the disease for
less than 5 years had a mean unit treatment cost of
$3,004, compared to $9,783 for those who had DM for
more than 20 years (Table 2).
Management costs of DM also varied with the mode
of diagnosis. Patients diagnosed incidentally had the
highest annual mean cost amounting to$8,055 compared
to only $3,585 for those diagnosed by screening, perhaps
due to the medical conditions that prompted the inci-
dental diagnosis (Table 2).
The annual mean treatments cost for patients on diet
control and without complications was US$ 1,605 (SD =
±$1,206) (Table 5). However, the presence of DM com-
plications substantially increased the average patient
treatment costs (Table 5). For example, the annual
mean treatment cost of patients on insulin is US$ 7,086
(SD ± $ 6425) and for those with hypertension the
annual mean cost was 6,210 (SD ± $6,132) (Table 5).
Annual treatment costs of patients with microvascular
complications were 2.2 times higher than the costs of
those without complications (Table 6 & Figure 1). DM
treatment costs of patients with macrovascular compli-
cations were 6.4 times higher than those without com-
plications and the costs of those with both micro and
macrovascular complications were 9.4 times higher.
Hospital costs constituted a large proportion of overall
treatment costs (Table 6 & Figure 2).
Estimates and associations were not substantially
affected by weighting cases (inversely) by frequency of
clinic attendance, suggesting that our sampling method
did not introduce substantial bias. As many of the factors
Table 2 Average Annual DM Treatment Costs in US $ by Patient Clinical Characteristics and Health Care Provider in
the UAE during 2004 (N = 150)
Patient Clinical Characteristics N % (95% C.I) Mean $ Annual Cost Std Deviation
Type of DM insulin treated 55 43% (35.1-50.9) 6,778 6,651
non insulin treated 94 57% (49.1-64.9) 3,995 4,941
Mode of Diagnosis Incidental 36 13% (7.6-18.4) 8,055 7,276
Screening 26 23% (16.3-29.7) 3,538 3,811
Symptomatic 88 63% (55.3-70.7) 5,213 6,021
Family History of DM Present 97 65.1% (57.4-72.8) 5,144 6,015
Absent 52 34.8% (27.2-42.4) 4,319 5,978
Current health care provider Primary Health Clinic 43 28.6% (21.3-35.9) 4,077 5,007
Hospital Diabetes specialist 70 46.6% (38.6-54.6) 6,117 6,315
Hospital ER 1 0.6% (-0.6-1.8) 16,923 0
Private clinic 34 22.6% (15.9-29.3) 3,576 5,382
Other health care provider 2 1(-0.5-2.5) 7,139 6,059
Duration of DM <=5 yrs 40 26% (19.2-33.2) 3,004 3,946
6 - 10 yrs 40 26% (19.2-33.2) 4,598 5,231
11 - 20 yrs 60 40% (31.8-47.4) 6,191 6,605
>=21 yrs 9 8% (3.7-12.5) 9,783 6,573
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analysis of covariance to identify which factors are inde-
pendently associated with (natural logarithm of) costs.
Possible sampling bias was corrected for by including the
frequency of clinic attendance as an additional co-vari-
able. Table (7) shows the results of this analysis. Variables
not significantly correlated with the dependent variable
were removed sequentially (i.e. backward selection) until
only (marginally) significant variables remained in the
model. Interestingly, type of diabetes (1 or 2) was not
included as it was not significantly associated with costs
after adjustment for treatment with insulin. Surprisingly,
unlike a history of myocardial infarction which was asso-
ciated with an exp (0.72) = 2.05 fold increase in costs, a
history of stroke was not associated with significantly
increased medical costs.
Table 3 Treatment Profile of DM Patients attending PHC
and Hospital Clinics in the UAE during 2004 (N = 150)
Variable N Percent
Annual Patients’ Visits to PHC or DM Clinics
1-2 visits 25 17%
3-6 visits 55 37%
7 - 11 visits 39 26%
12 or more visits 18 12%
Laboratory tests
HbA1c 72 50%
Fasting blood sugar 136 91%
Fasting lipid profile 103 69%
Renal function test 104 69%
Urine analysis 55 37%
Urine microscopy 94 63%
Microalbuminuria 73 49%
24 Hour collection for proteins and creatinine
clearance
43 29%
Hospitalization due to DM complications in the past year
Never 113 76.6%
1 time 22 14.6%
2-3 times 11 7.3%
4-5 times 4 2.6%
ER visits due to DM in the past year
Never 81 54%
1 time 29 19.3%
2-5 times 30 20%
More than 5 times 8 5.4%
Don’t know 2 1.3%
Table 4 Cardiovascular Risk and Treatment Profile of DM
Patients in the UAE during 2004 (N = 150)
Variable Percent
Dyslipidemia
Presence of dyslipidemia (High Cholesterol) 53.3%
Use of lipid lowering agents 44%
Hypertension
Use of antihypertensive agents 54%
Foot Complications
Prevalence of symptomatic neuropathy 81.3%








Prevalence of Stroke 8%
Observation and treatment at hospital ward 90%
Treatment with physiotherapy 9.1%
Duration of treatment for stroke at hospital ward
1 week or less 27%
2 weeks or more 73%
Diabetic Retinopathy
Prevalence of Retinopathy 58%
Patients undergone visual acuity test 42%
Patients had eye pressure measurement 46%
Patients undergone retinal imaging 40%
Patients undergone laser treatment 16.7%
Patients undergone operation for cataract extraction 20.7%
Diabetic Nephropathy
Prevalence of diabetic nephropathy 34%
Prevalence of chronic renal failure 13.6%
Patients with chronic renal failure who had undergone
hemodialysis
71%
Patients with chronic renal failure who had undergone
kidney transplantation
29%
Self reported general assessment of Health Status
poor health 61%
good health 39%
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This is the first study assessing the costs of diabetes
care in the UAE. Despite numerous limitations, the
study was able to assess and analyze DM patients’
management costs in the UAE and to present esti-
mates that would hopefully help directing attention to
the sizeable financial burden of the disease, for the
first time in the UAE. To do that the study analyzed
streams of DM patients’ management costs, based on
patients’ profiles, for those without DM complications
during one year. The study revealed that the average
management costs per diabetic patient without
complications in the UAE were $1,605 (SD ± $1,473)
compared to $5,645 (SD ± $5,966) for those with DM
complications. As expected costs were substantial but
varied significantly with the initial mode of diagnosis,
with the highest costs incurred by those diagnosed
incidentally. Delay in diagnosis can directly increase
complications and then lead to higher costs. Addition-
ally, the presence of DM related complications, conco-
mitant diseases such as hypertension, disease duration,
age, insulin dependence and a history of myocardial
infarction were shown to have multiplicative effect on
patients’ management costs. This clearly shows the
Table 5 Average Annual Treatment Costs in US $ by DM Patient Complications in the UAE during 2004 (Weighted, N =
150)
Patient Characteristics N % Average (Mean) $ Cost Std. Deviation
No DM related Complications Yes 47 31% 1,605 1,206
On insulin Yes 59 39.5% 7,086 6,739
No 90 60.5% 3,760 4,696
On oral hypoglycemic agents Yes 98 65.7% 4,262 5,043
No 51 34.2% 7,079 6,975
DM Eye related complications Yes 76 51% 6,445 6,590
No 57 38.2% 3,298 4,057
Don’t know 14 9.4% 5,957 6,601
Heart attack Yes 46 30.8% 5,557 8,230
No 103 69.2% 3,258 2,955
High cholesterol Yes 77 51.6% 6,532 6,786
No 60 40.2% 3,680 4,260
Don’t know 11 7.4% 3,681 4,105
Hypertension Yes 83 55.7% 6,210 6,432
No 66 44.3% 3,807 4,748
Stroke Yes 7 15.2% 7,261 5,073
No 39 84.8% 6,454 7,368
Foot or leg ulcer or sore not healed for more than a month Yes 53 35% 5,776 5,038
No 97 65% 4,887 6,308












1,605 3,453 10,300 15,104
Hospital Costs 135 358 761 541
Ratio 0 2.654500726 5.646071947 4.016776899
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cost. Similar conclusions have been drawn by other
studies [19,20].
Hospital admissions accounts for the largest part of
diabetes cost, the extra need for inpatient hospital care
for patients who have developed late complications will
greatly affect cost since hospital bed-day has a relatively
high unit cost compared with other resources and over-
all medication costs. Furthermore, most diabetics on
oral hypoglycemic agents receive insulin soon after hos-
pital admission for complications and this further
increase the costs.
Our estimates appear to be of the same order of mag-
nitude as those from Western countries, which seems
logical as health care facilities in the UAE are of similar
or even higher standard compared to those in many
developed countries [13]. The comparison with develop-
ing countries in Asia and Africa is more difficult due to
lack of information on patients’ health care expenditures
from most of these countries. However, where data are
available they suggest -as expected - much lower levels
of expenditure. For example, a recent study assessing
the treatment costs of diabetics in Karachi - Pakistan
[21] estimated the annual mean treatment costs per DM
patient to be $197 only. Another example is a recent
study from Iran in 2009, which gave an annual cost fig-
ure of US$ 152 per DM patient [9]. Similarly, in Tunisia,
an analysis in 1994 estimated an annual cost figure as
low as US$ 117 [10], in Egypt costs were even lower
[11] and a recent study in Sudan showed direct costs to
amount USD 175 per year [12]. Middle income coun-
tries, such as those in Latin America and the Caribbean
region, tend to be in-between Western and developing
countries [22]. Of course, treatment costs exclude many
intangible costs which are also very high in developing
countries. For example, the World Bank and WHO,
Figure 1 Effect of DM Complications on the Average Cost per Patient in the UAE during 2004 (n = 150).
Figure 2 Effect of DM Complications on Hospitalization Cost per Patient in the UAE during 2004 (n = 150).
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related to DM and its complications are incurred in
developing countries [23].
A major limiting factor of our study is that it did not
correct for costs that would have been incurred in the
absence of DM. For example, some vascular complica-
tions and costs incurred by them may have occurred in
the absence of DM. This may have led to some overesti-
mation of costs. By contrast, DM may have aggravated
conditions not considered in this study (e.g. hospitaliza-
tion duration after accidents) which may have led to
some underestimation of cost s .H o w e v e r ,b ys a m p l i n g
from patients attending clinics, we may have over-
sampled frequent attendees. Although we tried to com-
pensate for this using appropriate statistical technique
such as re-weighting, we cannot be absolutely sure that
this yields exactly the same results as a truly random
sample. Thus, our estimatess h o u l db et r e a t e dw i t h
caution.
Conclusions
In view of the present high prevalence of DM in the
UAE, and the potential costs associated with its manage-
ment, investments in prevention are expected to be
profitable and worthy. Likewise, the control of the con-
comitant risk factors for vascular complications, such as
obesity, dislipidemia, and hypertension are key elements
to reduce progression to these complications, and there-
fore, reduce the potential management costs associated
with them. However, the high prevalence of incidental
diagnosis among UAE patients, the primary source for
the high DM treatment costs, suggest that diabetes may
be under-diagnosed in the UAE population and tend to
remain unrecognized until major complications occur.
This suggests that the onset of the disease could be sub-
stantially reduced, and therefore the potential costs
associated with it, if the high risk population is screened
for DM on regular basis. However, to offset the poten-
tial costs of screening it may be worthy looking for
other risk factors as well, such as obesity, hypertension
or vascular diseases to help reducing their incidence,
and therefore further reducing the overall burden of
chronic diseases in the UAE.
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